Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Sunshine Biopharma, Inc | sbfm_ex991.htm |
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
October 6, 2020
SUNSHINE BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its
charter)
|
Colorado
|
000-52898
|
20-5566275
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID No.)
|
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
(Address
of principal executive offices)
514) 426-6161
(Issuer’s
Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 1.01 Entry into a Material Definitive Agreement
Effective
October 6, 2020, we entered into a Research Agreement (the
“Agreement”) with the University of Georgia Research
Foundation, Inc. (“UGARF”), a non-profit corporation
duly organized and existing under the laws of the State of Georgia,
the performance of which UGARF will subcontract to the University
of Georgia (“UGA”). The purpose of the Agreement is to
memorialize the terms of our working together with UGA to conduct
the necessary research and development to advance our
Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof)
through various stages of preclinical development, animal studies
and clinical trials for Coronavirus infections. The Agreement
grants us an exclusive worldwide license for all of the
intellectual property developed by UGA, whether alone or jointly
with us.
All of
the work in respect of the project to be performed within the
framework of the Agreement will be financed by us. As we recently
reported (Form 8-K filed on September 15, 2020), we have executed a
Financing Agreement with RB Capital Partners, Inc., La Jolla, CA,
pursuant to which RB Capital Partners, Inc. has agreed to provide
us with a minimum of $2 million in funding for Anti-Coronavirus
drug development over the next three to six months. On September
14, 2020, we received the initial $250,000 of this
financing.
We have
the right to terminate the Agreement at any time with a ninety (90)
day written notice. In the event such termination however, our
exclusive worldwide license will also be terminated.
Item 7.01 Regulation FD Disclosure
Our
Press Release relating to the Agreement is attached as Exhibit 99.1
and is hereby incorporated.
Item 9.01 Financial Statements and Exhibits
(b)
Exhibits. The following exhibits are included in this
report:
No.
Description
Press Release dated
October 19, 2020
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
SUNSHINE
BIOPHARMA, INC.
(Registrant)
|
|
|
|
|
|
|
|
|
Date: October 19,
2020
|
By:
|
/s/ Dr. Steve N.
Slilaty
|
|
|
|
|
Dr. Steve N.
Slilaty
|
|
|
|
|
Chief Executive
Officer
|
|